Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of XXXX cells.

@entity1 @entity17732 @entity64 @entity1148 @entity583 @entity63 @entity1423 @entity5 @entity117 @entity49 @entity4341 @entity6383 @entity1151 @entity887 @entity1188 @entity1031 @entity453 @entity1211 @entity715 @entity204
Four drugs that inhibit platelet function have been evaluated for their antithrombotic effects in @entity1 . These are @entity117 , @entity4341 , @entity6383 and @entity17732 . @entity117 has been shown to reduce the number of @entity63 ( @entity63 ), @entity64 and @entity204 in @entity1 with multiple @entity63 . The reduction in @entity63 was greatest in males who were normotensive and when there was an angiographically demonstrated lesion in the carotid artery that accounted for the symptoms. @entity117 reduced @entity49 and @entity1151 in @entity1 after surgery for fractured hip and after elective hip replacement. There is evidence that the prophylactic effect of @entity117 may be greater in male @entity1 . @entity117 reduced the frequency of arteriovenous shunt @entity715 . @entity117 abolished symptoms in @entity1 with @entity63 associated with @entity1148 and spontaneous @entity1423 . There is no conclusive evidence at the present time that @entity117 is effective in @entity1 with @entity453 . @entity4341 in combination with oral anticoagulants is effective in reducing the frequency of systemic @entity887 in @entity1 with prosthetic heart valve replacement but is ineffective in @entity1 with transient cerebral @entity63 attacks or for the prevention of @entity1211 . @entity6383 was effective in reducing postoperative @entity49 in @entity1 undergoing general abdominothoracic surgery but the evidence that it was effective in @entity1 undergoing orthopaedic surgery is inconclusive. @entity17732 may be effective in reducing the frequency of sudden @entity204 in @entity1 in the first year after @entity583 when it is started within 25 to 35 days after the @entity1188 . @entity17732 reduced the incidence of arteriovenous shunt @entity715 in @entity1 undergoing chronic hemodialysis and in combination with anticoagulants, it reduced the frequency of recurrent @entity49 . There have been no large scale trials of platelet suppressant drugs in clinical @entity5 and successful treatment of @entity1031 cannot be used to predict success in the treatment of @entity5 .
